{Reference Type}: Journal Article
{Title}: The 2023 Orthopedic Research Society's international consensus meeting on musculoskeletal infection: Summary from the in vitro section.
{Author}: Hickok NJ;Li B;Oral E;Zaat SAJ;Armbruster DA;Atkins GJ;Chen AF;Coraça-Huber DC;Dai T;Greenfield EM;Kasinath R;Libera M;Marques CNH;Moriarty TF;Scott Phillips K;Raghuraman K;Ren D;Rimondini L;Saeed K;Schaer TP;Schwarz EM;Spiegel C;Stoodley P;Truong VK;Tsang SJ;Wildemann B;Zelmer AR;Zinkernagel AS;
{Journal}: J Orthop Res
{Volume}: 42
{Issue}: 3
{Year}: 2024 Mar 25
{Factor}: 3.102
{DOI}: 10.1002/jor.25774
{Abstract}: Antimicrobial strategies for musculoskeletal infections are typically first developed with in vitro models. The In Vitro Section of the 2023 Orthopedic Research Society Musculoskeletal Infection international consensus meeting (ICM) probed our state of knowledge of in vitro systems with respect to bacteria and biofilm phenotype, standards, in vitro activity, and the ability to predict in vivo efficacy. A subset of ICM delegates performed systematic reviews on 15 questions and made recommendations and assessment of the level of evidence that were then voted on by 72 ICM delegates. Here, we report recommendations and rationale from the reviews and the results of the internet vote. Only two questions received a ≥90% consensus vote, emphasizing the disparate approaches and lack of established consensus for in vitro modeling and interpretation of results. Comments on knowledge gaps and the need for further research on these critical MSKI questions are included.